Open AccessCombined Intracervical PGE 2 and Intra‐Amniotic PGF 2α for Induction of 2nd Trimester Abortion
Author(s) -
Allen Jim,
Maigaard Svend,
Forman Axel,
Ulmsten Ulf,
Hansen K. P. Brogaard
Publication year - 1987
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348709022064
Subject(s) - medicine , abortion , oxytocin , gestational age , amniotic fluid , obstetrics , pregnancy , fetus , amniotic sac , gestation , gynecology , endocrinology , biology , genetics
Fourteen consecutive patients (mean gestational age 18.1 weeks, range 15‐23 weeks) referred for therapeutic termination of pregnancy were induced into abortion by intra‐amniotic PGF 2α 40 mg followed by oxytocin stimulation. 14 other patients (mean gestational age 17.9 weeks, range 15‐23 weeks) were pretreated with intracervical PGE 2 1.0 mg in gel for 4 h prior to induction of abortion with intra‐amniotic PGF 2α 40 mg without further stimulation. The induction‐abortion interval for patients treated with intra‐amniotic PGF 2α and oxytocin, was 19.1 ± 2.94 h (±SE, n=14) with a success rate of 80% after 24 h. After pretreatment with intracervical PGE 2α 1.0 mg in viscous gel, intra‐amniotic PGF 2α 40 mg induced abortion after 11.2 ± 1.12 h (± SE, n = 14) with a 100% success rate after 24 h. No systemic side effects of the PGE 2 pretreatment were noted. No cervical laceration was observed. The results need further confirmation, but still suggest cervical priming with intracervical PGE 2 1.0 mg in gel and subsequent induction of abortion by intra‐amniotic PGF 2α 40 mg as an attractive principle for 2nd trimester abortion.